Neuromyelitis optica is distinct from multiple sclerosis

Archives of Neurology

Volumn 64, Issue 6, 2007, Pages 899-901

  Weinshenker, Brian G ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA INTERFERON; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; OLIGOCLONAL BAND;

ARTICLE; B LYMPHOCYTE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLONAL VARIATION; DEMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; LABORATORY DIAGNOSIS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; RADIODIAGNOSIS; RESPIRATORY FAILURE; SYMPTOM;

DIAGNOSIS, DIFFERENTIAL; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

EID: 34250347276     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.6.899     Document Type: Article

References (15)

1. Weinshenker BG, Miller D. MS: one disease or many? In: Siva A, Kesselring J, Thompson A, eds. Frontiers in Multiple Sclerosis. London, England: Martin Dunitz, Ltd; 1999:37-46.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53:1107-1114.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-1489.
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-2112.
5. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60:382-387.
6. de Seze J, Stojkovic T, Ferriby D, et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002;197:57-61.
7. Misu T, Fujihara K, Nakashima I, et al. Pure opticspinal form of multiple sclerosis in Japan. Brain. 2002;125:2460-2468.
8. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125:1450-1461.
9. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219-1220.
10. Zuliani L, Lopez de Munain A, Ruiz Martinez J, et al. Anticuerpos IgG-NMO en la neuromielitis optica: proposito de 2 casos. Neurologia. 2006;21:314-317.
11. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica - clinical predictors of a relapsing course and survival. Neurology. 2003;60:848-853.
12. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390-396.
13. Weinshenker BG, Wingerchuk D, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse following longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566-569.
14. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal MS binds to the aquaporin 4 water channel. J Exp Med. 2005;202:473-477.
15. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. 2001;7:115-121.